In last trading session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw 1.08 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $5.37 trading at $0.32 or 6.34% at ring of the bell on the day assigns it a market valuation of $369.07M. That closing price of EYPT’s stock is at a discount of -340.41% from its 52-week high price of $23.65 and is indicating a premium of 6.89% from its 52-week low price of $5.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.78 million shares which gives us an average trading volume of 823.58K if we extend that period to 3-months.
For EyePoint Pharmaceuticals Inc (EYPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Upright in the green during last session for gaining 6.34%, in the last five days EYPT remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $5.37 price level, adding 14.08% to its value on the day. EyePoint Pharmaceuticals Inc’s shares saw a change of -27.92% in year-to-date performance and have moved -11.39% in past 5-day. EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) showed a performance of -11.68% in past 30-days. Number of shares sold short was 10.83 million shares which calculate 13.37 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 75.59% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -309.68% in reaching the projected high whereas dropping to the targeted low would mean a loss of -309.68% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -22.68% while estimates for its earnings growth in next 5 years are of 0.67%.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
Insiders are in possession of 1.16% of company’s total shares while institution are holding 109.63 percent of that, with stock having share float percentage of 110.92%. Investors also watch the number of corporate investors in a company very closely, which is 109.63% institutions for EyePoint Pharmaceuticals Inc that are currently holding shares of the company. CORMORANT ASSET MANAGEMENT, LP is the top institutional holder at EYPT for having 8.32 million shares of worth $72.43 million. And as of 2024-06-30, it was holding 15.6467 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 5.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7279 of outstanding shares, having a total worth of $45.03 million.
On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.04 shares of worth $10.95 million or 2.97% of the total outstanding shares. The later fund manager was in possession of 1.99 shares on Dec 31, 2024 , making its stake of worth around $10.68 million in the company or a holder of 2.89% of company’s stock.
